IL169099A0 - Use of a combination containing a non-nucleoside revrse transcriptase inhibitor (nnrti) with an inhibitor of cytochrome p450, such as protease inhibitors - Google Patents

Use of a combination containing a non-nucleoside revrse transcriptase inhibitor (nnrti) with an inhibitor of cytochrome p450, such as protease inhibitors

Info

Publication number
IL169099A0
IL169099A0 IL169099A IL16909905A IL169099A0 IL 169099 A0 IL169099 A0 IL 169099A0 IL 169099 A IL169099 A IL 169099A IL 16909905 A IL16909905 A IL 16909905A IL 169099 A0 IL169099 A0 IL 169099A0
Authority
IL
Israel
Prior art keywords
inhibitor
revrse
nnrti
cytochrome
nucleoside
Prior art date
Application number
IL169099A
Other languages
English (en)
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of IL169099A0 publication Critical patent/IL169099A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/75—Rutaceae (Rue family)
    • A61K36/752—Citrus, e.g. lime, orange or lemon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medical Informatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Botany (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL169099A 2002-12-16 2005-06-09 Use of a combination containing a non-nucleoside revrse transcriptase inhibitor (nnrti) with an inhibitor of cytochrome p450, such as protease inhibitors IL169099A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43369002P 2002-12-16 2002-12-16
PCT/EP2003/014224 WO2004054586A1 (en) 2002-12-16 2003-12-15 Use of a combination containing a non-nucleoside reverse transcriptase inhibitor (nnrti) with an inhibitor of cytochrome p450, such as protease inhibitors

Publications (1)

Publication Number Publication Date
IL169099A0 true IL169099A0 (en) 2007-07-04

Family

ID=32595224

Family Applications (1)

Application Number Title Priority Date Filing Date
IL169099A IL169099A0 (en) 2002-12-16 2005-06-09 Use of a combination containing a non-nucleoside revrse transcriptase inhibitor (nnrti) with an inhibitor of cytochrome p450, such as protease inhibitors

Country Status (20)

Country Link
US (2) US20040152625A1 (enExample)
EP (1) EP1575595A1 (enExample)
JP (1) JP2006511538A (enExample)
KR (1) KR20050085681A (enExample)
CN (1) CN1726041A (enExample)
AU (1) AU2003296647A1 (enExample)
BR (1) BR0317095A (enExample)
CA (1) CA2510143A1 (enExample)
EA (1) EA200500894A1 (enExample)
EC (1) ECSP055854A (enExample)
HR (1) HRP20050557A2 (enExample)
IL (1) IL169099A0 (enExample)
MX (1) MXPA05005773A (enExample)
NO (1) NO20053455L (enExample)
NZ (1) NZ541187A (enExample)
PL (1) PL376900A1 (enExample)
RS (1) RS20050461A (enExample)
UA (1) UA81003C2 (enExample)
WO (1) WO2004054586A1 (enExample)
ZA (1) ZA200502947B (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1944042A1 (en) 2003-10-27 2008-07-16 Vertex Pharmceuticals Incorporated Combinations for HCV treatment
US7388008B2 (en) 2004-08-02 2008-06-17 Ambrilia Biopharma Inc. Lysine based compounds
US20060287316A1 (en) * 2005-04-27 2006-12-21 Ambrilia Biopharma Inc. Method for improving pharmacokinetics of protease inhibitors and protease inhibitor precursors
WO2007062526A1 (en) 2005-11-30 2007-06-07 Ambrilia Biopharma Inc. Lysine-based prodrugs of aspartyl protease inhibitors and processes for their preparation
CN1907138B (zh) * 2006-08-11 2011-01-12 华南师范大学 一种沙田柚子汁提取物及其提取方法和应用
ES2628730T3 (es) 2006-09-21 2017-08-03 Taimed Biologics, Inc. Inhibidores de proteasa
SG174146A1 (en) 2009-02-27 2011-10-28 Enanta Pharm Inc Hepatitis c virus inhibitors
LT2421527T (lt) * 2009-04-25 2018-09-10 F. Hoffmann-La Roche Ag Farmakokinetinių savybių pagerinimo būdai
CA2761650C (en) 2009-05-13 2015-05-26 Enanta Pharmaceuticals, Inc. Macrocyclic compounds as hepatitis c virus inhibitors
US8653070B2 (en) 2009-12-14 2014-02-18 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
WO2014013014A1 (en) 2012-07-18 2014-01-23 Fundació Privada Centre De Regulació Genòmica (Crg) Jak inhibitors for activation of epidermal stem cell populations
WO2018041989A1 (en) 2016-09-02 2018-03-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for diagnosing and treating refractory celiac disease type 2
WO2020201362A2 (en) 2019-04-02 2020-10-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of predicting and preventing cancer in patients having premalignant lesions
WO2020212395A1 (en) 2019-04-16 2020-10-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of jak inhibitors for the treatment of painful conditions involving nav1.7 channels
US20250283174A1 (en) 2022-05-16 2025-09-11 Institut National de la Santé et de la Recherche Médicale Methods for assessing the exhaustion of hematopoietic stem cells induced by chronic inflammation
WO2026093435A1 (en) 2024-10-31 2026-05-07 Institut National de la Santé et de la Recherche Médicale Use of jak inhibitors for enhancing the potency of immunotherapy in the treament of cancer

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5696270A (en) * 1989-05-23 1997-12-09 Abbott Laboratories Intermediate for making retroviral protease inhibiting compounds
IL111991A (en) * 1994-01-28 2000-07-26 Abbott Lab Liquid pharmaceutical composition of HIV protease inhibitors in organic solvent
US6037157A (en) * 1995-06-29 2000-03-14 Abbott Laboratories Method for improving pharmacokinetics
CA2285577A1 (en) * 1997-04-07 1998-10-15 Triangle Pharmaceuticals, Inc. Compositions containing mkc-442 in combination with other antiviral agents
HK1040625B (zh) * 1998-11-04 2005-04-01 法玛西雅厄普约翰美国公司 用於改善替普拉那维的药物动力学的方法
US6391919B1 (en) * 2000-01-12 2002-05-21 Bristol-Myers Squibb Pharma Company Bis-amino acid sulfonamides containing substituted benzyl amines HIV protease inhibitors
TWI270547B (en) * 2000-06-16 2007-01-11 Boehringer Ingelheim Ca Ltd Non-nucleoside reverse transcriptase inhibitors
DE60306539T2 (de) * 2002-09-19 2007-07-19 Boehringer Ingelheim (Canada) Ltd., Laval Nicht-nukleosidische inhibitoren der reverse transkriptase

Also Published As

Publication number Publication date
ZA200502947B (en) 2008-01-30
ECSP055854A (es) 2006-01-16
UA81003C2 (en) 2007-11-26
CN1726041A (zh) 2006-01-25
MXPA05005773A (es) 2005-08-16
NO20053455L (no) 2005-08-10
KR20050085681A (ko) 2005-08-29
BR0317095A (pt) 2005-10-25
HRP20050557A2 (en) 2006-05-31
EA200500894A1 (ru) 2006-02-24
CA2510143A1 (en) 2004-07-01
WO2004054586A1 (en) 2004-07-01
EP1575595A1 (en) 2005-09-21
RS20050461A (sr) 2007-08-03
US20080096832A1 (en) 2008-04-24
JP2006511538A (ja) 2006-04-06
US20040152625A1 (en) 2004-08-05
AU2003296647A1 (en) 2004-07-09
NZ541187A (en) 2007-12-21
PL376900A1 (pl) 2006-01-09

Similar Documents

Publication Publication Date Title
PL376900A1 (pl) Zastosowanie kombinacji zawierającej nienukleozydowy inhibitor odwrotnej transkryptazy (NNRTI) i inhibitor cytochromu P450, taki jak inhibitor proteazy
MX2010006738A (es) Inhibidores de proteasa del virus de la hepatitis c (hcv) y usos de los mismos.
MX2010006736A (es) Inhibidores de proteasa del virus de la hepatitis c (hcv) y usos de los mismos.
PL378556A1 (pl) Nienukleozydowe inhibitory odwrotnej transkryptazy
AU2003269628A1 (en) Non-nucleoside reverse transcriptase inhibitors
DK1797281T3 (da) Fremgangsmåde til at estimere et bruds geometri, såvel som sammensætninger og artikler anvendt dertil
AP2006003551A0 (en) Combinations of a pyrimidine containing NNRTI withRT inhibitors.
AP2004003191A0 (en) Pseudopolymorphic forms of HIV protease inhibitor.
EP1483254A4 (en) INHIBITORS OF ANTI-RESISTANCE RETROVIRAL PROTEASE
SG148179A1 (en) Benzyltriazolone compounds as non-nucleoside reverse transcriptase inhibitors
TWI372619B (en) Non-nucleoside reverse transcriptase inhibitors
GB0329470D0 (en) Portable expandable project table
IL163753A0 (en) Non-nucleoside reverse transcriptase inhibitors
SG144941A1 (en) Naphthylene derivatives as cytochrome p450 inhibitors
AU2003234630A1 (en) Cysteine protease inhibitors
AU2003290735A1 (en) Inhibitors of monoamine uptake
AP1878A (en) Broadspectrum 2-amino-benzothiazole sulfonamide HIV protease inhibitors.
AU2003256305A1 (en) Peptidic compounds as cysteine protease inhibitors
IL157543A0 (en) Cyclopropaheterocycles as non-nucleoside reverse transcriptase inhibitors
PL372226A1 (en) Pyridineamido derivatives as inhibitors of monoamine oxidase (mao-b)
AU2003260908A1 (en) Pyrazole derivatives as reverse transcriptase inhibitors
HRP20041215A2 (en) Process and intermediates for making non-nucleoside hiv-1 reverse transcriptase inhibitors
UA96269C2 (uk) Інгібітори цистеїнпротеази та їх терапевтичне застосування
AU2003263738A1 (en) Protease inhibitors
AU2003274059A8 (en) Combination of a trioxopyrimidine compound inhibitor and an anti-tumor agent, and uses thereof